What check size does Iain Dukes write?

Iain Dukes typically writes checks of $1M – $75M.

What companies did Iain Dukes found?

Iain Dukes founded Eilean Therapeutics, Lomondther.

What boards does Iain Dukes sit on?

Iain Dukes holds tracked board seats at Angiex, Ikena Oncology, Inc..

Where did Iain Dukes go to school?

Iain Dukes studied at University of Oxford (MA, Jurisprudence (Law)); University of Oxford (DPhil, Physiology/Pharmacology); University of Leeds (MSc, Cardiovascular Studies).

Iain Dukes

InvestorFounder

Venture Partner at OrbiMed · Chief Business Officer / Chairman of the Board at Brenig · Board director at Theseus Pharmaceuticals · Board director at Angiex

Philadelphia, Pennsylvania

Writes $1M – $75M checks · typically $4M

FoundedEilean Therapeutics Lomondther

Find your path to Iain

820 people in our graph can introduce you to Iain.

Each arrow is one introduction. Sign up to fill in the first one.

Ask Roger Ulrich to introduce you to Iain

You →Roger · together at Kartosthera (2018–2026) →Iain

Ask Jamie Chen to introduce you to Iain

You →Jamie · together at Iovance Biotherapeutics →Iain

Ask Sam Okafor to introduce you to Iain

You →Sam · 10 people · together at GlaxoSmithKline →Iain

Your email: the people you already email who know Iain
2nd- and 3rd-degree connections: people you know who worked, studied or invested with Iain
Your LinkedIn: the connections who can make the intro for you

We rank every route by how warm it is, so you raise on warm intros instead of cold emails.

About

Iain Dukes is a Venture Partner at Orbimed and CEO of Viriom Inc, serving on the executive teams or boards of nine companies across the USA, France, and the UK. His career includes roles as Senior Vice President of Business Development & Licensing at Merck, where he managed licensing deals for Merck Research Laboratories, as well as Vice President of External Research and Development at Amgen, President and CEO of Essentialis Therapeutics, and Vice President of Scientific and Technology Licensing at GlaxoSmithKline. He holds a BSc in Pharmacology from the University of Bath, an MSc in Cardiovascular Studies from the University of Leeds, a DPhil in Physiology and Pharmacology from the University of Oxford, and an MA in Jurisprudence and Law from the University of Oxford.

Chief Business Officer / Chairman of the Board at Brenig

Intro paths

→

In turn, Iain can intro founders to Brenig's investors below.

Brenig's investors · 4

BGVSilicon Valley New Enterprise Associates (NEA)Menlo Park · $200K – $40M checks OrbiMedNew York · $1M – $75M checks Torrey Pines InvestmentSan Diego

Board director at Theseus Pharmaceuticals

Intro paths

→

In turn, Iain can intro founders to Theseus Pharmaceuticals's investors below.

Theseus Pharmaceuticals's investors · 9

Foresite CapitalWest Hollywood · since 2018 Longitude CapitalMenlo Park · $10M – $30M checks · since 2021 Nextech InvestZurich · $648K – $3.2M checks · since 2021 NexTech VenturesPrague · since 2021 Omega FundsBoston · since 2021 OrbiMedNew York · $1M – $75M checks · since 2018 Pontifax Venture CapitalHerzeliya · since 2021 Rock Springs CapitalBaltimore · since 2021 T. Rowe PriceBaltimore · since 2021

Co-founders at Theseus Pharmaceuticals

William C. ShakespeareDirector

Board director at Angiex

Intro paths

→

In turn, Iain can intro founders to Angiex's investors below.

Angiex's investors · 3

Green Meadow VenturesWest Hollywood · $500K – $3M checks · since 2017 K5 GlobalSan Francisco · $1M – $3M checks · since 2017 OrbiMedNew York · $1M – $75M checks · since 2025

Co-founders at Angiex

Paul JaminetExecutive Officer, Director

Experience

Viriom IncCEOcurrent2019 — presentSan Diego, CA
Theseus PharmaceuticalsCEOcurrent2018 — presentCambridge, MA
ENYO PharmaBoard Membercurrent2018 — presentLyon, France
KaNDY Therapeutics, Ltd.Chairman of the Boardcurrent2017 — presentStevenage, UK
Kartos TherapeuticsPresidentcurrent2017 — present
NeRRE Therapeutics, Ltd.Board Membercurrent2017 — presentStevenage, England, United Kingdom
ReViral, Ltd.Board Membercurrent2016 — presentStevenage, England, United Kingdom
Iovance Biotherapeutics, Inc.Chairman of the Boardcurrent2016 — presentSan Carlos, CA
Kyn Therapeutics, Inc.Board Membercurrent2016 — presentBoston, MA
OrbiMedVenture Partnercurrent2016 — presentNew York, NY
MerckSVP Licensing & External Science2013 — 2016Upper Gwynedd, Pa
AmgenVP External R&D2010 — 2013
Biotech ConsultingPresident2009 — 2010Greater Philadelphia
Essentialis TherapeuticsPresident & CEO2007 — 2009San Diego County, California, United States
GlaxoSmithKlineVP Scientific and Technology Licensing2000 — 2007Research Triangle Park, NC

Skills & more

Biotechnology6R&D11FDA4Pharmaceutical Industry10Drug Discovery6Licensing11Clinical Development6Lifesciences3Strategy4Drug Development11Biopharmaceuticals13Technology Transfer3

+4 more

Business DevelopmentOncologyLife SciencesCommercialization

From Iain's professional profile.

Deals · 2

AngiexBoard seat

via OrbiMed · filed Sep 2025 · $28.4M raise

Ikena Oncology, Inc.Board seat

via OrbiMed · filed Jul 2025 · $75M raise

Attribution from SEC filings, press coverage, and firm rosters.

Leave your own feedback

Colleagues at OrbiMed

Alexander M. Cooper

Investor at OrbiMed

Anat Nursella

Venture Partner at OrbiMed

Andrew P. Kanarek, CFA, CIPM

Venture Partner at OrbiMed

Frequently asked questions

Who is Iain Dukes?: Iain Dukes is a Venture Partner at Orbimed and CEO of Viriom Inc, serving on the executive teams or boards of nine companies across the USA, France, and the UK. His career includes roles as Senior Vice President of Business Development & Licensing at Merck, where he managed licensing deals for Merck Research Laboratories, as well as Vice President of External Research and Development at Amgen, President and CEO of Essentialis Therapeutics, and Vice President of Scientific and Technology Licensing at GlaxoSmithKline. He holds a BSc in Pharmacology from the University of Bath, an MSc in Cardiovascular Studies from the University of Leeds, a DPhil in Physiology and Pharmacology from the University of Oxford, and an MA in Jurisprudence and Law from the University of Oxford.
Where does Iain Dukes work?: Iain Dukes is CEO of Eilean Therapeutics and Venture Partner at OrbiMed and Chief Business Officer / Chairman of the Board at Brenig and Board director at Theseus Pharmaceuticals and Board director at Angiex.
What check size does Iain Dukes write?: Iain Dukes typically writes checks of $1M – $75M.
What companies did Iain Dukes found?: Iain Dukes founded Eilean Therapeutics, Lomondther.
What boards does Iain Dukes sit on?: Iain Dukes holds tracked board seats at Angiex, Ikena Oncology, Inc..
Where did Iain Dukes go to school?: Iain Dukes studied at University of Oxford (MA, Jurisprudence (Law)); University of Oxford (DPhil, Physiology/Pharmacology); University of Leeds (MSc, Cardiovascular Studies).